期刊
BONE MARROW TRANSPLANTATION
卷 46, 期 6, 页码 863-869出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/bmt.2010.201
关键词
human herpesvirus-6; hematopoietic stem cell transplantation; alternative donors; limbic encephalitis; foscarnet sodium
资金
- Ministry of Health, Labour and Welfare of Japan [19-1]
Human herpesvirus-6 (HHV-6) is a major cause of limbic encephalitis with a dismal prognosis after allogeneic hematopoietic SCT (HSCT). A prospective, multicenter study was conducted to assess the safety and efficacy of preemptive therapy with foscarnet sodium (PFA) for the prevention of HHV-6 encephalitis. Plasma HHV-6 DNA was measured thrice weekly from day 7 until day 36 after umbilical cord blood transplantation (UCBT) or HSCT from HLA-haploidentical relatives. PFA, 90 mg/kg/day, was started when HHV-6 DNA exceeded 5 x 10(2) copies/mL. Mild and transient adverse events were associated with PFA in 7 of 8 patients. Twelve of 15 UCBT recipients became positive for HHV-6 DNAemia, defined by greater than 1 x 10(2) copies/mL of HHV-6 DNA in plasma. The virus exceeded 5 x 10(2) copies/mL in seven patients, whereas none of the five HLA-haploidentical HSCT recipients became positive. One patient developed mild limbic encephalitis just after initial PFA administration. Preemptive PFA therapy is safe, but as HHV-6 DNAemia can abruptly develop before neutrophil engraftment in UCBT recipients, prophylactic PFA administration from day 7 or earlier after UCBT may be needed. Bone Marrow Transplantation (2011) 46, 863-869; doi: 10.1038/bmt.2010.201; published online 13 September 2010
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据